Efficacy and safety of supramolecular salicylic acid in the treatment of papulopustular rosacea: a multicentre randomized, double-blind, placebo-controlled superiority study
Clinical and Experimental Dermatology · 25.11.2025 · 50 (12) · 2410-2417
DOI: 10.1093/ced/llaf316 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 24.07.2025. Verfasst von Xian Jiang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Rosacea, Salicylic Acid, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Shanghai Ruizhi Medical Technology Co. Ltd.
Abstract (Originalsprache)
Background
Rosacea is a chronic inflammatory skin disorder with a complex aetiology involving genetic, immunological and environmental factors. Although various treatments are available, managing papulopustular lesions remains challenging. Salicylic acid, known for its anti-inflammatory properties, has been used in dermatology for decades, but its efficacy in treating rosacea needs further exploration.
Objectives
To investigate the effectiveness and safety of 30% supramolecular salicylic acid (SSA) in treating papulopustular rosacea.
Methods
We conducted a prospective multicentre, randomized, double-blind, placebo-controlled trial involving 480 patients aged 18–60 years with papulopustular rosacea. Participants were randomized 1 : 1 to receive either 30% SSA or placebo every 2 weeks for 6 weeks, with follow-up assessments up to week 8. The study assessed primary and secondary efficacy endpoints, including lesion reduction rates, Investigator’s Global Assessment (IGA) and Investigator’s Severity Assessment (ISA) scores, VISIA® red area improvements and skin barrier functions, and evaluated safety and tolerability.
Results
The SSA group showed a significant improvement in the primary efficacy endpoint at week 8, with efficacy rates of 51.3% [full-analysis set (FAS)] and 59.9% [per-protocol set (PPS)], compared with 18.3% (FAS) and 20.5% (PPS) in the placebo group (P < 0.001 for both). Secondary endpoints also favoured SSA, demonstrating improved lesion reduction, IGA and ISA scores, and skin condition. Safety profiles were comparable between the SSA and placebo groups, with no significant difference in adverse event rates.
Conclusions
Our findings highlight the superior efficacy of 30% SSA in improving papulopustular rosacea symptoms compared with a placebo, coupled with a favourable safety and tolerability profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology & Venereology, West China Hospital, Sichuan University, Chengdu, China.
- Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University,…
ORCID-Profile: Juan Tao
Förderung
- Shanghai Ruizhi Medical Technology Co. Ltd
Zitieren
APA
Jiang, X., Lai, W., Gao, X., Zeng, W., Tao, J., Li, Y., Yu, N., Li, J., Lu, Q., Xiao, R., Xiong, Y., Yang, J., Zhang, L., Chen, J., Chen, X. E., Sun, N., Tao, S., Xu, N., Zhou, Y., …, & Yang, E. (2025). Efficacy and safety of supramolecular salicylic acid in the treatment of papulopustular rosacea: a multicentre randomized, double-blind, placebo-controlled superiority study. Clinical and Experimental Dermatology, 50(12), 2410-2417. https://doi.org/10.1093/ced/llaf316
Vancouver
Jiang X, Lai W, Gao X, Zeng W, Tao J, Li Y, et al. Efficacy and safety of supramolecular salicylic acid in the treatment of papulopustular rosacea: a multicentre randomized, double-blind, placebo-controlled superiority study. Clinical and Experimental Dermatology. 2025;50(12):2410-2417. doi:10.1093/ced/llaf316
BibTeX
@article{Jiang2025,
author = {Jiang, Xian and Lai, Wei and Gao, Xinghua and Zeng, Weihui and Tao, Juan and Li, Yuzhen and Yu, Nan and Li, Ji and Lu, Qianjin and Xiao, Rong and Xiong, Ying and Yang, Jie and Zhang, Litao and Chen, Jin and Chen, Xu-E and Sun, Nana and Tao, Shiqin and Xu, Nan and Zhou, Yongan and Ye, Juan and Zhang, Fan and Yang, Enpin},
title = {Efficacy and safety of supramolecular salicylic acid in the treatment of papulopustular rosacea: a multicentre randomized, double-blind, placebo-controlled superiority study},
journal = {Clinical and Experimental Dermatology},
year = {2025},
volume = {50},
number = {12},
pages = {2410--2417},
doi = {10.1093/ced/llaf316}
}
EUVIMED